




Technical Market View

The S&P 500 closed nearly unchanged last week despite dipping back to the 50-MA again on Wednesday where buyers showed up yet again. We bounced back strong and closed right at monthly VPOC on Friday. We're forming a loose consolidation under 4,185 over the last two weeks and bull wedge under recent highs. The late-week momentum is starting to lift the 8-EMA higher and potential for a bullish cross above the 21-MA this week around 4,160. That would put price back above all its key moving averages and momentum firmly to the upside and break of this month-long chop. A key area to watch is 4,200 which is the top of May value while 4,270, 4,320, and 4,400 in focus. Support below is 4,100 at the low-end of May value, 4,050, and then a low-volume gap from March back to 3,970.



Market Sentiment/Breadth

The latest AAI sentiment survey for the week ending 5/19 showed a slight rise in bulls to 37% vs 36.5% prior while bears fell to 26.3% vs 27%. Both are slightly below their long-term averages while neutral sentiment is 36.7% and well above historical levels. NAAIM fell slightly this week to 44.21 and surprisingly the lowest print since April 2020. As of Friday's close there were 311 new highs vs 27 new lows, strong breadth but not near its peak in April. Similarly, the percentage of S&P 500 stocks above their 200-day MA was 91.38% and remains well off the peak in April. NYSE Summation was 535.89 and fell again last week and remains well below its 8-EMA, a bearish/cautious signal. NASI is also below its 8-EMA but starting to curl higher and actually near a bull cross. Cumulative AD is just below new highs. CBOE Equity P/C 50-day MA was 0.53 and pulling back from its recent peak. NYMO was -2.29. CNN Fear and Greed was 34 and near its lowest level for all of 2021.

Market Event Outlook

Monday: Fed's Brainard, Mester, George and Bostic Speak; **International Data:** Singapore CPI, Taiwan Industrial Production, BOJ's Kuroda Speaks; **Earnings After the Close:** CRMT, RIDE, API, NDSN, ARCE, YQ; **Analyst Days:** ABNB; **Conferences:** Coinbase Consensus Conference, JP Morgan TMT (ERIC, SEDG, IRBT, NATI, CALX, ANET, BKI, DOX, AXON, AI, PTCT, TENB, AKAM, FEYE, PTC, CSCO, TRMB, MSFT, V, FTNT, ADP, ST, EXTR, Q TWO, JCOM, MA, ONTF, AVL R, DT, CTSH, UBER, ATUS, DBX, BAND, EQIX, BE, WISH, SPNS, CRT O, HAS, ALTR, LYFT, TTMI, MXL, VRNS, PEGA, KEYS, GPRO, FCN, DOCN, PRO, FVRR, ZI, SBAC, QCOM, GLW, EVOP, TWTR, RBBN, NSIT, LRCX, XPER, EVER, JBL, LITE, INTC, ALRM, ZNGA, INOV, FIS, BCE, BKNG, MU, CCI, FIVN, HUBS, JNPR, CMCSA, TSP, FROG), UBS Healthcare (DNLI, ABBV, AHCO, ALNY, ALXO, AMWL, ANGO, ANIK, AMEH, APLT, APR, ARWR, AXSM, BAX, BHVN, BNTX, BTAI, BSX, CCCC, CLPT, CDXS, CRY, CYRX, CVAC, CTSO, DMTK, EAR, LLY, EHC, ESTA, EXAS, FMS, FRE.DE, FME.DE, GLPG, GSK, HCA, HRC, ICLR, INMD, IART, IVC, JAZZ, KOD, LMAT, LIVN, MRVI, MRNS, MASI, MDT, MSON, MOR, NBTX, NSTG, NTUS, NVRO, NFH, NVS, NRIX, OSUR, ORTX, PACB, RGNX, RCKT, PHIA.NL, PHG, RPRX, TNDM), Wolfe Transports (R, GP, FTAI, MMM, TT, CSX, HON, UNP, USX, GE, TSP, VNT, WERN, CARR, AAL, CMI, SNCY, ARVL, DAL, PH, GTES, UAL, JCI, ROK, SWK, VRT, NSC, HA, FTV, NVT, AAON, MATX)

Tuesday: Consumer Confidence, Fed's Quarles Speaks, New Home Sales, API Inventories; **International Data:** German GDP, German IFO; **Earnings Before the Open:** AZO, CBRL, ITRN, DY, CTRN, HTHT, MMYT, VSAT, BNR, ESLT; **Earnings After the Close:** A, INTU, JWN, ZS, SOL, URBN, TOL, SKY, RAMP, VNET, HEI, RRGB, ESEA; **Analyst Days:** YUM; **Conferences:** JP Morgan TMT, UBS Healthcare, UBS Oil and Gas (BRY, MNRL, COP, ESTE, FLMN, ICD, KRP, KMI, KOS, MGY, NOG, TALO, TDW, WES, SLB, BKR, CDEV, CHK, XEC, DEN, DVN, HES, MUR, OV V, PBA, PSX, PXD, RRC, FTI), Wolfe Transports

Wednesday: Bank CEOs on Capitol Hill, EIA Inventories; **International Data:** New Zealand Rate Decision; **Earnings Before the Open:** DKS, PDD, LI, ANF, BMO, CPRI, BBW, PLAB, REX, CMCO, EVGN, BQ; **Earnings After the Close:** NVDA, SNOW, APPS, OKTA, WDAY, WSM, ZUO, NTNX, AEO, DBI, PSTG, ELF, DXC, NXGN, OOMA, UHAL, CVCO, MOD, CHNG, QADA, LAIX; **Analyst Days:** F, DCO, OMI, SU, TROW, VSTO; **Conferences:** JP Morgan TMT, UBS Healthcare, UBS Oil and Gas, Wolfe Transports

Thursday: Bank CEOs on Capitol Hill, Durable Goods, GDP, Weekly Claims, Pending Home Sales; **International Data:** China Industrial Profits, South Korea Rate Decision, German Consumer Climate, Japan Employment; **Earnings Before the Open:** BBY, DG, DLTR, MDT, ATHM, RDHL, TD, PLAN, RY, TITN, BURL, HLNE, MOV, GCO, SAFM, CM, HHR, MIXT, AMWD, THR; **Earnings After the Close:** CRM, COST, ULTA, VEEV, BOX, ADSK, GPS, OLLI, QFIN, VMW, DELL, HPQ, GES, YY, DOMO, YEXT, FANH, ASND, LGF'A, AFYA ; **Analyst Days:** ALTR, MRNA, RJF; **Conferences:** Wolfe Transports

Friday: Core PCE, Personal Spending, Chicago PMI, Michigan Consumer Sentiment; **International Data:** EU Consumer Confidence, EU Business Climate; **Earnings Before the Open:** BIG, HIBB, FRO, CAL, MDNA

Weekly Open Interest Radar

Yeti (YETI) shares holding up well recently and flagging above the rising 50-MA and prior range with plenty of room for upside on a breakout. The May value-area high is just above at \$88.25 and a breakout has a measured move to \$100. Shares closed above the 8-, 13-, and 21-day MA on Friday and both MACD and RSI have reset and ready to run. YETI has seen a lot of bullish put sales lately across August and January while the August \$90 calls have been bought over 3,500X since 5/6, sizable positioning over \$2.4M. The \$7.32B company trades 31.8X earnings, 6.27X sales, and 38.5X cash. YETI is coming off of a strong quarter with gross margins expanding 700 bps and turning more investments toward International growth and channel expansion. The company is also focused on data analytics and other digital capabilities which will improve overall targeting and inventory rationalization. Analysts have an average target for shares of \$86.75 and a Street High \$115. BAML raising estimates on 5/14 citing their outlook on Yeti's continued domestic momentum

and significant long-term international opportunity. CSFB positive as well with a \$105 PT noting that the brand remains underpenetrated in large parts of the country, its international business is nascent, and there is opportunity to enter new product categories, thus expanding its addressable market. Short interest is 7.4%. Hedge fund ownership rose 7.75% in Q1. Leonard Green a buyer of call options and Wilkinson Global buyer of 500,000 shares.

Trade to Consider: Long the YETI August \$90 Calls for \$7 or Better



Weekly Options Technical Trade Set-Up

Ticker	MSFT
Trigger Level	\$248.40
Call/Put	Calls
Strike	\$250
Target	\$255
Stop	\$244.75



Insider Trade of the Week

OpenDoor (OPEN) with a large open market buy on 5/19 from a director, Pueo Keffer, of 67,700 shares at \$14.75, a nearly \$1M purchase. This is the first open market buy from an insider in the name since it went public in 2020. OPEN has traded poorly in 2021 down around 33% and back around a big area of interest from late 2020 before the stock when on a strong run. OPEN is forming a larger bull wedge and a breakout above \$18 can make a big trend shift back higher. The \$8.18B company trades 3.16X sales and 3.89X cash with 92% growth expected in FY21 and 83% in FY22. Opendoor is an online marketplace for home sellers, like others like Redfin and Zillow. OPEN is growing at a fast rate and expanding their platform into more buying of homes as well as their trade-in program which helps customers both sell their home and buy a home in one transaction. OPEN uses AI and analytics to model out value for homes and help drive better sales margins on their inventory. They noted in May that the current environment is experiencing the fastest home price appreciation in decades with multiple offers and higher conversion rates. In Q1 they set several records including offers, seller conversion, and launching in new markets. Analysts have an average target for shares of \$36.50 and a Street High \$72. OpCo with a \$25 PT on 5/12 and the analyst is increasingly bullish on Opendoor's market opportunity, given comments of servicing \$1.4M home in LA, suggesting a bigger SAM than expected. Additionally, the recent launch of Opendoor-Backed Offers positions the company to assist buyers, better positioning Opendoor to serve both sides of the transaction and drive higher attach rates of adjacent services. Short interest is 4.72%. Hedge fund ownership rose 3% in Q1, CandleStick Capital a top buyer of 1.16M shares.


Earnings Preview

Capri Holdings (CPRI) reporting earnings on Wednesday before the Open with the Street looking for \$0.01 on \$1.01B in sales. Next quarter is guided to \$0.55 and \$1.01B while the FY is \$1.51 and \$3.88B. Shares have a strong history closing higher in each of the last three and four of the last five with an average closing move of 8.4% and a max move of 11.4%. The \$7.45B company trades 14.2X earnings, 1.84X sales, and 14.7X FCF. CPRI has seen strength in all three of their main luxury brands while citing strength in Q3 from the America's and Asia. The company should benefit in Q4 from better conditions in EMEA which was hit hard by closures in late 2020. CPRI should also see better margins as they execute on initiatives to limit promotions and markdowns as well as selectively raising prices. They also should have a positive read-through from other luxury names this quarter which have continued to show demand standing out among the apparel segment. Analysts have an average target for shares of \$47 with a Street High \$75. BMO raising estimates on 5/3 as the stock has been a top intra-COVID-19 performer but it also remains near the bottom relative to its group on a multi-year basis in spite of the material self-help-driven earnings upside and the reopening/stimulus benefits. OTR Global upgrading to Positive on 4/15 as the firm's checks indicate Michael Kors same-store-sales year-over-year improved dramatically in China during FYQ3 and FYQ4, while U.S. outlet sales received a boost from stimulus checks. Short interest is 3.3%, the lowest since August 2019. Hedge fund ownership fell 7% in Q1, Junto Capital adding a new position. CPRI has seen a lot of bullish flow including buyers in the June \$55 calls and the June \$60/\$65 call spread last week. The June \$57.50 calls have also been bought 3,000X while the November \$75 calls with 3,500 in OI from buyers. On the chart, CPRI has upside to \$58.50 on the chart while support is below around \$48 which is VWAP for the year.


Date	Description	Volume	Open.In	Price	Delt	Impl Vo	Prob.ITN	Premium Pai
5/20/2021	CPRI 100 18 JUN 21 55 CALL	1,012	283	\$3.00	0.47	58.83%	40.67%	\$303,600
5/19/2021	CPRI 100 18 JUN 21 65 CALL	2,500	81	\$0.85	0.18	59.48%	13.75%	\$227,500
5/19/2021	CPRI 100 18 JUN 21 60 CALL	2,108	1,170	\$1.82	0.33	58.24%	26.90%	\$389,980
5/19/2021	CPRI 100 18 JUN 21 57.5 CALL	1,363	1,289	\$2.70	0.42	59.87%	35.56%	\$370,736
5/5/2021	CPRI 100 19 NOV 21 75 CALL	2,143	19	\$3.35	0.31	48.37%	19.32%	\$750,050
4/23/2021	CPRI 100 18 JUN 21 57.5 CALL	1,011	28	\$2.81	0.404	49.96%	32.99%	\$284,091

Top 40 Micro-Cap Profile of the Week

Renalytix AI (RNLX) is a UK-based company that came public in June of 2020, and is an artificial intelligence-enabled *in vitro* diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Its diagnostics platform, KidneyIntelX, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk. KidneyIntelX has already been granted a common procedural terminology, national Medicare pricing and a positive coverage determination from a regional, private physician-led health insurance payor.



CKD affects approximately 37 million individuals in the United States, significantly impacting their quality of life and resulting in Medicare spending of over \$120B per year. Treatment for kidney failure consumes 6.7% of the total Medicare budget to care for less than 1% of the covered population. In the United States, dialysis costs approximately \$90,000 per patient per year and a kidney transplant costs approximately \$260,000, with annual follow-up costs averaging approximately \$40,000. According to the National Kidney Foundation, more than two million people worldwide are currently treated with dialysis or kidney transplants, making CKD a global public health crisis.



The KidneyIntelX platform will be central to managing CKD, helping to identify which patients could benefit from clinical interventions at earlier stages of CKD before significant and irreversible kidney damage has taken place. For patients with CKD as a result of diabetes, obesity or other factors, early intervention can lower the risk of progressing to life-altering advanced disease, kidney failure, dialysis, suffering and diminished quality of life. The KidneyIntelX artificial intelligence-enabled algorithm integrates the composite of feature inputs into a continuous patient risk score, which is reported to the treating clinician on a scale from 0 to 100 and also categorized into low-, intermediate- and high-risk strata. This novel capability of using machine learning-enabled algorithm to generate a continuous risk score enables the timely and accurate prediction of risk of disease progression in the earlier stages of DKD, where active intervention has the most potential to delay or prevent progression to ESKD and the need for dialysis or kidney transplant.

For primary care physicians and specialists, KidneyIntelX provides an easy-to-understand, reportable patient risk score integrated with specific guideline-driven clinical recommendations designed to maximize patient treatment and compliance outcomes. For insurance payors, KidneyIntelX can help drive health economics gains over time. For population health and clinical medicine departments, KidneyIntelX provides a powerful prognostic tool to stratify CKD populations into low-, intermediate- and high-risk categories applied to a continuous scale, enabling physicians to optimize the choice of treatment and allocation of clinical resources to benefit patient outcomes and health economics.

RNLX currently has a market cap of \$980M and although not seen earning much in the term of revenues in 2021, the forecast sees strong growth and reaching \$250M+ in revenues by 2025 with profitability seen in 2023. According to the Centers for Disease Control and Prevention, in the United States alone, CKD affects approximately 37 million people and DKD, the most common type of CKD, affects approximately 12.6 million adults. Based on the Centers for Medicare & Medicaid Services, or CMS, national price for KidneyIntelX of \$950 per reportable test, this represents a potential market opportunity of approximately \$12 billion assuming one test per patient.

RNLX is actively pursuing Medicare coverage determination under the Molecular Diagnostics Services, or MolDX, Program, which would expand Medicare coverage and expedite the claims payment process. It also plans the launch of KidneyIntelX in major medical markets outside of the United States, including in the United Kingdom, European Union and China, which have large and growing populations of CKD patients and are facing cost and clinical management challenges similar to the United States. There is also the opportunity of extending KidneyIntelX application into additional populations of CKD patients beyond those with diabetes, including patients of African ancestry with the *APOL1* high-risk genotype. RNLX has established key partnerships with Mount Sinai, DaVita, AstraZeneca and others.

RNLX is clearly a futuristic play that you are paying for the longer-term potential of its platform, one that appears to be differentiated and attacking a massive opportunity. It is an early-stage company but one within a growing diagnostics industry crossing over with key technology megatrends that has the potential to be transformational.

May 28th (W) OpEx Notable Open Interest

Date	Description	Volume	Current	Current Price	Price Change	Current Value	OI Different
4/29/2021	AAPL 100 (Weeklys) 28 MAY 21 133 PUT	10,102	13619	\$8.95	132.47%	\$12,189,005.00	22.92%
5/14/2021	QCOM 100 (Weeklys) 28 MAY 21 110 CALL	1,666	4256	\$19.70	-4.18%	\$8,384,320.00	155.31%
5/10/2021	SNOW 100 (Weeklys) 28 MAY 21 195 CALL	1,545	1766	\$36.00	183.46%	\$6,357,600.00	12.84%
4/23/2021	BA 100 (Weeklys) 28 MAY 21 250 PUT	1,676	2115	\$26.75	49.86%	\$5,657,625.00	18.75%
5/5/2021	ZM 100 (Weeklys) 28 MAY 21 300 CALL	3,000	3168	\$17.20	-6.42%	\$5,448,960.00	3.87%
5/19/2021	AAPL 100 (Weeklys) 28 MAY 21 127 PUT	4,463	13847	\$3.44	-18.10%	\$4,763,368.00	90.10%
5/20/2021	FB 100 (Weeklys) 28 MAY 21 320 CALL	10,108	10,108	\$4.48	0%	\$4,528,384.00	0%
4/15/2021	BABA 100 (Weeklys) 28 MAY 21 230 PUT	1,257	2305	\$18.49	173.93%	\$4,261,945.00	63.59%
4/22/2021	APPS 100 (Weeklys) 28 MAY 21 72 PUT	2,100	2100	\$12.48	104.59%	\$2,620,800.00	0.00%
4/29/2021	MU 100 (Weeklys) 28 MAY 21 87 PUT	1,236	3130	\$7.75	101.30%	\$2,425,750.00	143.77%
5/6/2021	ANF 100 (Weeklys) 28 MAY 21 40 CALL	4,316	8044	\$3.00	-2.91%	\$2,413,200.00	86.16%
5/5/2021	ZM 100 (Weeklys) 28 MAY 21 320 CALL	3,003	3929	\$5.90	-31.40%	\$2,318,110.00	26.74%
5/13/2021	AMZN 100 (Weeklys) 28 MAY 21 3300 CALL	1,030	878	\$25.00	19.05%	\$2,195,000.00	-51.38%
4/16/2021	SNOW 100 (Weeklys) 28 MAY 21 230 PUT	320	1489	\$14.65	10.98%	\$2,181,385.00	359.57%
4/26/2021	LMT 100 (Weeklys) 28 MAY 21 370 CALL	571	1369	\$14.15	56.70%	\$1,937,135.00	139.34%
4/15/2021	SNOW 100 (Weeklys) 28 MAY 21 225 PUT	315	1468	\$11.90	14.42%	\$1,746,920.00	354.49%
4/26/2021	BAC 100 (Weeklys) 28 MAY 21 41 CALL	9,969	11553	\$1.37	80.26%	\$1,582,761.00	9.52%
4/30/2021	SWKS 100 (Weeklys) 28 MAY 21 170 PUT	1,545	2572	\$6.10	235.16%	\$1,568,920.00	64.56%
5/20/2021	YY 100 (Weeklys) 28 MAY 21 87 CALL	3,000	3,000	\$5.15	0%	\$1,545,000.00	0%
5/18/2021	SNAP 100 (Weeklys) 28 MAY 21 57.5 CALL	20,263	20275	\$0.76	-8.43%	\$1,540,900.00	-2.32%
5/17/2021	LOW 100 (Weeklys) 28 MAY 21 192.5 PUT	2,033	2614	\$5.63	15.84%	\$1,471,682.00	-0.11%
5/13/2021	JD 100 (Weeklys) 28 MAY 21 70 CALL	3,708	7030	\$2.04	-5.12%	\$1,434,120.00	87.22%
5/10/2021	GOTU 100 (Weeklys) 28 MAY 21 25.5 CALL	10,000	10044	\$1.37	-39.11%	\$1,376,028.00	0.43%
4/23/2021	BA 100 (Weeklys) 28 MAY 21 227.5 PUT	1,539	1903	\$7.20	16.69%	\$1,370,160.00	15.26%
4/22/2021	BLK 100 (Weeklys) 28 MAY 21 795 CALL	564	365	\$37.51	74.47%	\$1,369,115.00	-35.40%
4/13/2021	FB 100 (Weeklys) 28 MAY 21 300 CALL	502	848	\$15.80	-27.52%	\$1,339,840.00	68.59%
5/13/2021	PDD 100 (Weeklys) 28 MAY 21 133 CALL	2,670	2659	\$5.02	177.35%	\$1,334,818.00	-1.01%
5/19/2021	ABNB 100 (Weeklys) 28 MAY 21 140 CALL	2,458	3082	\$4.30	14.67%	\$1,325,260.00	-18.12%
5/20/2021	PDD 100 (Weeklys) 28 MAY 21 152.5 CALL	8,093	8,093	\$1.60	0%	\$1,294,880.00	0%
4/27/2021	SWKS 100 (Weeklys) 28 MAY 21 175 PUT	1,100	1217	\$10.31	587.33%	\$1,254,727.00	8.66%
5/6/2021	SWKS 100 (Weeklys) 28 MAY 21 167.5 PUT	2,299	2565	\$4.75	82.69%	\$1,218,375.00	-6.25%
5/11/2021	PDD 100 (Weeklys) 28 MAY 21 145 CALL	2,507	5423	\$2.12	25.44%	\$1,149,676.00	97.56%
5/17/2021	AMD 100 (Weeklys) 28 MAY 21 80 CALL	6,571	16307	\$0.67	42.55%	\$1,092,569.00	65.12%
4/22/2021	BLK 100 (Weeklys) 28 MAY 21 805 CALL	589	362	\$29.34	77.28%	\$1,062,108.00	-38.95%
4/12/2021	CRM 100 (Weeklys) 28 MAY 21 222.5 PUT	722	1440	\$7.35	6.52%	\$1,058,400.00	98.07%
5/20/2021	EXAS 100 (Weeklys) 28 MAY 21 107 CALL	3,082	3,082	\$3.30	0%	\$1,017,060.00	0%
5/20/2021	UBER 100 (Weeklys) 28 MAY 21 49.5 CALL	8,437	8,437	\$1.19	0%	\$1,004,003.00	0%
4/13/2021	NIO 100 (Weeklys) 28 MAY 21 35 PUT	5,153	4088	\$2.32	13.73%	\$948,416.00	-21.29%

Date	Description	Volume	Current	Current Price	Price Change	Current Value	OI Different
4/23/2021	DLTR 100 (Weeklys) 28 MAY 21 115 PUT	1,189	1878	\$5.00	25.00%	\$939,000.00	49.40%
5/7/2021	UAL 100 (Weeklys) 28 MAY 21 53 CALL	1,408	2752	\$3.28	20.15%	\$902,656.00	23.35%
5/13/2021	CRM 100 (Weeklys) 28 MAY 21 222.5 CALL	1,124	1457	\$6.08	60.00%	\$885,856.00	2.90%
5/18/2021	DKS 100 (Weeklys) 28 MAY 21 81.5 PUT	3,355	3302	\$2.65	82.76%	\$875,030.00	-1.99%
5/19/2021	SQ 100 (Weeklys) 28 MAY 21 200 CALL	1,039	1159	\$6.98	26.91%	\$808,982.00	-21.74%
5/3/2021	LOW 100 (Weeklys) 28 MAY 21 195 PUT	2,060	1090	\$7.35	72.94%	\$801,150.00	-49.75%
5/10/2021	MRNA 100 (Weeklys) 28 MAY 21 155 CALL	1,029	1030	\$7.55	-31.36%	\$777,650.00	-8.04%
4/16/2021	SIRI 100 (Weeklys) 28 MAY 21 6.5 PUT	12,501	12721	\$0.60	36.36%	\$763,260.00	0.07%
4/26/2021	SPLK 100 (Weeklys) 28 MAY 21 129 PUT	492	545	\$13.85	207.78%	\$754,825.00	9.66%
4/29/2021	APO 100 (Weeklys) 28 MAY 21 55 CALL	1,090	3851	\$1.93	13.53%	\$743,243.00	247.56%
5/14/2021	ZM 100 (Weeklys) 28 MAY 21 330 CALL	2,191	2202	\$3.30	-5.71%	\$726,660.00	-21.86%
5/6/2021	SPOT 100 (Weeklys) 28 MAY 21 220 PUT	1,002	954	\$7.25	57.61%	\$691,650.00	-51.38%
4/26/2021	HON 100 (Weeklys) 28 MAY 21 220 CALL	656	2003	\$3.45	-44.44%	\$691,035.00	202.57%
5/12/2021	AMAT 100 (Weeklys) 28 MAY 21 125 CALL	1,328	1675	\$3.96	80.00%	\$663,300.00	20.33%
5/20/2021	IQ 100 (Weeklys) 28 MAY 21 14 CALL	14,637	14,637	\$0.43	0%	\$629,391.00	0%
5/20/2021	ETSY 100 (Weeklys) 28 MAY 21 175 CALL	1,461	1,461	\$4.30	0%	\$628,230.00	0%
4/30/2021	SNOW 100 (Weeklys) 28 MAY 21 250 CALL	415	1013	\$6.10	-8.68%	\$617,930.00	104.65%
5/20/2021	UAA 100 (Weeklys) 28 MAY 21 21.5 CALL	10,592	10,592	\$0.58	0%	\$614,336.00	0%
5/20/2021	SNAP 100 (Weeklys) 28 MAY 21 57 CALL	4,798	4,798	\$1.24	0%	\$594,952.00	0%
4/22/2021	SNOW 100 (Weeklys) 28 MAY 21 220 CALL	414	346	\$17.00	-15.00%	\$588,200.00	-22.94%
5/7/2021	SYF 100 (Weeklys) 28 MAY 21 46 CALL	3,047	3516	\$1.64	31.20%	\$576,624.00	14.86%
4/12/2021	BAC 100 (Weeklys) 28 MAY 21 40 CALL	2,027	2770	\$2.07	29.38%	\$573,390.00	33.43%
5/3/2021	KSS 100 (Weeklys) 28 MAY 21 66 CALL	2,165	5070	\$1.10	-49.31%	\$557,700.00	68.61%
5/3/2021	KSS 100 (Weeklys) 28 MAY 21 58 PUT	2,165	3018	\$1.83	-15.67%	\$552,294.00	0.50%
5/13/2021	RVLV 100 (Weeklys) 28 MAY 21 43 CALL	1,563	1515	\$3.53	-1.94%	\$553,795.00	-3.50%
5/19/2021	SNAP 100 (Weeklys) 28 MAY 21 59 CALL	10,050	10072	\$0.50	0.00%	\$503,600.00	-2.77%
4/23/2021	MCD 100 (Weeklys) 28 MAY 21 235 PUT	672	659	\$7.23	10.38%	\$476,457.00	-14.19%
5/10/2021	VIPS 100 (Weeklys) 28 MAY 21 22 PUT	2,007	5014	\$0.91	65.45%	\$456,274.00	149.70%
4/27/2021	ON 100 (Weeklys) 28 MAY 21 38 PUT	2,500	2516	\$1.78	304.55%	\$447,848.00	0.28%
5/10/2021	GOTU 100 (Weeklys) 28 MAY 21 32 CALL	10,001	10084	\$0.44	-12.00%	\$443,696.00	0.80%
5/19/2021	WFC 100 (Weeklys) 28 MAY 21 48 CALL	10,007	13036	\$0.33	0.00%	\$430,188.00	1.92%
4/15/2021	WMB 100 (Weeklys) 28 MAY 21 24.5 CALL	2,073	2249	\$1.87	266.67%	\$420,563.00	8.39%
5/6/2021	RKT 100 (Weeklys) 28 MAY 21 19 PUT	1,811	2110	\$1.98	98.00%	\$417,780.00	10.99%
5/20/2021	MRNA 100 (Weeklys) 28 MAY 21 170 CALL	1,037	1,037	\$4.00	0%	\$414,800.00	0%
5/20/2021	YY 100 (Weeklys) 28 MAY 21 100 CALL	2,551	2,551	\$1.55	0%	\$395,405.00	0%
5/19/2021	XOM 100 (Weeklys) 28 MAY 21 58.5 CALL	5,035	2599	\$1.50	0.00%	\$389,850.00	-50.24%
4/16/2021	GOLD 100 (Weeklys) 28 MAY 21 21.5 CALL	1,542	1007	\$3.85	200.78%	\$387,695.00	-37.18%
5/19/2021	XOM 100 (Weeklys) 28 MAY 21 60 CALL	4,080	4885	\$0.75	-6.25%	\$366,375.00	-11.07%

Technical Scans

BULL SCANS

Notable 8/21 EMA Bull Crossovers: GOOGL, SHOP, SNOW, ADI, EW, VRTX, IDXX, EBAY, DDOG, ZBRA, ABC, WORK, LOGI, ALNY, CRL, ZLAB, TEVA, WTRG, BHC, MCFE, BRKR, MKSI, AZPN, BBIO, KRC, REXR, DNLI, CHNG, ASAN, ORCC, MGP, BHVN, SFIX, SIGI, KRNT, CELH, ITRI, ISBC, BZUN, GBDC, RPAY, GTH, PING, NWBI, IRT, TTMI, QURE, GPRE, VECO, BHE

Notable 13/34 EMA Bull Crossovers: INFY, F, AWK, ZBRA, CCL, WORK, YNDX, LOGI, GME, DBX, ARCC, CUZ, PSTH, CUK, CNX, COOP, AMRC, BLUE, KYMR, SPNT, TTCF, CCCC, PRCH, BHE, RADI, CARS, COLL, CTLP, PBYI

Notable 21/55 EMA Bull Crossovers: HRL, ZTO, ACIW, CELH, WWE, APOG, STIM, MRNS, CTLP

Emerging Strength (Daily RSI Cross of 50 w/ Accumulation/Distribution Ratio at 12 Week High): BWA, WMS, TX, TCF, RCM, EXP, ISBC, ADNT

20 Day Highs with Strong Closes: TM, NVO, MS, C, RY, HDB, CVS, PLD, CME, CM, CNC, CPRT, EQR, LYV, AGR, LNT, KRC, JOBS, SIGI, MSP, PFSI, SFBS, AQUA, FCFS, KAR, VSTO, IPOE, RDNT, ECPG

OBV 3 Month High: TM, NVO, BMY, RY, SE, TGT, MDLZ, ZTS, INFY, CB, COF, CL, BMO, IBN, CM, IDXX, BK, CNC, BBVA, HSY, PEG, SLF, PTON, CCEP, MTD, TSN, RMD, AWK, AVB, DTE, GRMN, MXIM, WST, IMO, GWW, AEE, ETR, FE, EXPD, LYV, TW, AKAM, RJF, CAG, BXP, DRE, ELAN, AGR, NLOK, LKQ, LNT, BSY, IPG, NLY, UPST, WTRG, BRKR, JAZZ, CSL, AGNC, DXC, BERY, ARW, PSXP, EHC, ADT, JBL, TX, YETI, REXR, SRCL, AIRC, NCR, MSA, SGMS, EVR, VRM, VVV, MPLN, NVT, LEGN, NOMD, FEYE, SAIC, IGT, JOBS, HRB, UNVR, MSP, EBC, BRFS, SXT, SUN, ALKS, FSKR, JW.A, MMSI, BLKB, IBTX, ATRC, ITCI, SSTK, FHI, BNL, DEN, MIME, CVBF, MIC, ITGR, UCBI, THS, PRMW, FSK, NVMI, MLI, WHD, FFBC, CRC, VRRM, PRFT, BDN, PGRE, UE, VSTO, CNR, XPEL, ROIC, ESRT, AVNS, EGBN, PACK, VBTX, ESTA, FRO, CLB, OAS, WIRE, CASH, PMVP, WLL, GOGL, PTGX, MGPI, BPMP, SBSI, BHLB, RDNT, OCFC, STBA, RGR, BIF, BRKL, STNG, OFG, CRY, CTS, AGRO, RFP, OCSL, DCOM, CUBI, PAHC, CNOB, BRBR, AWF, VREX, NTP, UMH, ANGO, TILE, NTST, TCPC, TIG, SMMT, SKIN, XENE, CFB, IDT, CLAR, GNK, CO, CUTR, LPI, THR, CMO, PLYM, TNK, DSU, MBI, FBRX, CAMP, CDZI, ANVS, ONCR, ZIXI

BEAR SCANS

Notable 8/21 Bear EMA Crossovers: CVX, NSC, BBL, URI, SCCO, DGX, IEP, ATR, RL, PAG, SKX, AEO, LIVN, SNDR, ATKR, BKE

Notable 13/34 EMA Bear Crossovers: VZ, NKE, ECL, HEI, BBY, WSM, PSN, KSS, TREX, URBN, SR, EPRT, RUTH, ALDX

Notable 21/55 EMA Bear Crossovers: WMG, GDDY, SMG, OZON, BLD, APG, TMHC, OGS, VRNT, FLR, UTZ, CENX, DRQ, WGO, RDUS, FF

Notable 34/144 EMA Bear Crossovers: TWLO, ABMD

Notable 55/233 EMA Bear Crossovers: SPOT, LITE, GO

Emerging Weakness (Daily RSI Cross Under 40 w/ Accumulation/Distribution Ratio at 6 Week Low): TJX, MFC, VFC, TPX, GDS, AYX, SYNA, KBH

20 Day Lows with Weak Closes: UNP, TJX, CNI, BBL, PGR, GPN, HPQ, DHI, VFC, LEN, PKX, WY, TAL, CLX, EDU, DISCA, MAS, DISCK, GDDY, RH, WSM, SMG, TPR, TREX, CHGG, FND, ATHM, UAA, BCH, BSAC, BLDR, RL, KSS, UTHR, RGA, UA, CPRI, PII, BC, RNR, NTRA, AXTA, SKX, TPX, NYT, COLM, THO, LSTR, AEO, TRIP, OLLI, KMPR, UFPI, PK, FCN, AXS, MSTR, PSN, KBH, LIVN, MDC, SWX, SR, ALLO, CWH, HUAYA, SLQT, URBN, ABM, NKTR, ENR, BIPC, PZZA, GSHD, VNET, VNOM, MEOH, EGHT,

CAKE, DY, SNBR, PRLB, WGO, ANF, OMAB, STRA, HIMX, RCUS, GBIO, CYTK, NWN, LTC, DK, KURA, SWM, CAN, HZO, CGEM, CENX, TBPH, NRIX, TVTX, KRA, OCUL, QUOT, OMER

OBV 3 Month Low: CNI, BBL, TDG, DAL, Z, SIRI, TAL, PCG, AMCR, WMG, DISCA, TDY, SAM, PENN, FFIV, ATHM, CLF, KC, NVST, JWN, ONEM, ABCM, ALLO, AAON, NSP, LXP, VSAT, GSHD, JELD, PRLB, DOYU, GRWG, XHR, DCPH, CALM, RCUS, YEXT, LTC, KURA, IPOF, AIR, BJRI, KROS, TVTX, KRA, CHRS, OMER, TRIL, MRUS, ARCT, VSTA, TPCO, ICPT, FF, IMPX, PRVB, BDTX, CLW, SGTX, SYRS, DGNS, EIGR

Disclaimer:

Not Investment Advice or Recommendation

Any descriptions "to buy", "to sell", "long", "short" or any other trade related terminology should not be seen as a recommendation. The Author may or may not take positions in any of the names mentioned, and is not obligated to disclose positions, nor position sizes.

Content is for informational and educational purposes only. You alone will need to evaluate the merits and risks associated with the use of this content. Decisions based on information provided are your sole responsibility, and before making any decision on the basis of this information, you should consider (with or without the assistance of a financial and/or securities adviser) whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. Investors should seek financial advice regarding the suitability of investing in any securities or following any investment strategies.

No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security. Nothing constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, we have not taken into account the investment needs, objectives and financial circumstances of any particular investor. This information has no regard to the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors.